Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Shravanti Macherla"'
Autor:
Kun Wang, Sanna Iivanainen, Jussi Pekka Koivunen, Abdul Rafeh Naqash, Mahvish Muzaffar, Shravanti Macherla, James Clark, Joo Sang Lee, Eytan Ruppin, David J Pinato, Emma Mi, Daria Gramenitskaya, Sweta Jonnalagadda, Shanker Polsani, Paul R Walker, Justin D McCallen, Mona A Marie, Rahim Ali Jiwani, Maida Hafiz, Leonardo Brunetti, Chipman R G Stroud, Youngmin Chung, Li V Yang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Systemic immune activation, hallmarked by C-reactive protein (CRP) and interleukin-6 (IL-6), can modulate antitumor immune responses. In this study, we evaluated the role of IL-6 and CRP in the stratification of patients with non-small cel
Externí odkaz:
https://doaj.org/article/a4e218a69ddc41e3b8ebe5105e3ff547
Autor:
Abdul Rafeh Naqash, Shravanti Macherla, Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Domenico Mallardo, Thomas Marron, Douglas Johnson, Christopher Hoimes, Vito Vanella, Toni Choueiri, Paolo Ascierto, Ella Daniels, Haocan Song, Fei Ye, Tamara Sussman, Domenico Galetta, Anwaar Saeed, Annamaria Catino, Carlo Genova, Pamela Pizzutilo, Giuseppe Lamberti, David Pinato, Rebecca Irlmeier, Caroline Nebhan, Weijie Ma, Teja Ganta, Neha Debnath, Maluki Radford, Asrar Alahmadi, Akiva Diamond, Nikhil Ramaiya, Carolyn Presley, Dwight Owen, Sarah Abou Alaiwi, Amin Nassar, Chiara Casartelli, Maria Giovanna Dal Bello, Foteini Kalofonou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d3d2c8bfadc44b14b83c47b19f5d8ab6
Autor:
Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang, Mahvish Muzaffar, Mona A. Marie, Justin D. Mccallen, Shravanti Macherla, Darla Liles, Paul R. Walker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract Background Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believed to be related to i
Externí odkaz:
https://doaj.org/article/8fb76ca2c40e4edd93e37771226ab1ae
Autor:
Abdul Rafeh Naqash, Mahvish Muzaffar, Shravanti Macherla, Alessio Cortellini, James Clark, Emma Mi, Sanna Livanainen, Daria Gramenitskaya, Kevin O’Brien, Jussi Koivunen, Sweta Jonnalagadda, Shanker Polsani, Rahim Jiwani, Nitika Sharma, Chipman Stroud, Paul Walker, David Pinato
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/40e3e79742894243b4bf4802423f20b5
Autor:
Biagio Ricciuti, MD, Abdul Rafeh Naqash, MD, Jarushka Naidoo, MD, Kartik Sehgal, MD, Adam Miller, MD, Kenneth Kehl, MD, MPH, Deepti Venkatraman, MPH, Jacob Sands, MD, Giuseppe Lamberti, MD, Gonzalo Recondo, MD, PhD, Jiajia Zhang, MD, Shravanti Macherla, MD, Sameer Baig, MD, Paul Walker, MD, Deepa Rangachari, MD, Justin F. Gainor, MD, Daniel B. Costa, MD, Naiyer Rizvi, MD, Lynette M. Sholl, MD, Mizuki Nishino, MD, MPH, Brian Henick, MD, Anna F. Farago, MD, PhD, Mark M. Awad, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100074- (2020)
Introduction: The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and NSCLC. Whether this association exists in patients wit
Externí odkaz:
https://doaj.org/article/44c33d5b25fc49e0a525d0f78bde07d6
Autor:
Shravanti Macherla, Shachar Laks, Abdul Rafeh Naqash, Anushi Bulumulle, Emmanuel Zervos, Mahvish Muzaffar
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 11, p 3505 (2018)
Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, urothelial, and renal canc
Externí odkaz:
https://doaj.org/article/44932219ac04440c8b2e8de4dce0f46f
Publikováno v:
Cureus.
Autor:
Alessio Cortellini, Douglas B. Johnson, Amin Nassar, Sebastiano Buti, Pamela Pizzutilo, Fei Ye, Shravanti Macherla, David J. Pinato, Asrar Alahmadi, Giuseppe Lamberti, Anwaar Saeed, Ella Daniels, Paolo A. Ascierto, Carolyn J Presley, Sarah Abou Alaiwi, Melissa Bersanelli, Maluki Radford, Foteini Kalofonou, Tamara A. Sussman, Akiva Diamond, Maria Giovanna Dal Bello, Christopher J. Hoimes, Paolo Marchetti, Domenico Mallardo, Weijie Ma, Rebecca Irlmeier, Teja Ganta, Raffaele Giusti, Andrea Botticelli, Neha Debnath, Caroline A. Nebhan, Carlo Genova, Toni K. Choueiri, Biagio Ricciuti, Abdul Rafeh Naqash, Nikhil H. Ramaiya, Annamaria Catino, Haocan Song, Vito Vanella, Marco Filetti, Yinghong Wang, Thomas U. Marron, Chiara Casartelli, Dwight H. Owen, Domenico Galetta
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundImmune checkpoint inhibitors (ICIs) are approved by the U.S. Food&Drug Administration in over 17 tumor types. Older adult patients make up about a quarter of all cancer patients but are historically understudied in cancer clinical trials. I
Autor:
Justin F. Gainor, Jiajia Zhang, Anna F. Farago, Biagio Ricciuti, Sameer Baig, Mizuki Nishino, Adam Miller, Paul R. Walker, Kartik Sehgal, Daniel B. Costa, Mark M. Awad, Jacob Sands, Deepa Rangachari, Deepti Venkatraman, Brian S. Henick, Gonzalo Recondo, Naiyer A. Rizvi, Shravanti Macherla, Giuseppe Lamberti, Abdul Rafeh Naqash, Jarushka Naidoo, Lynette M. Sholl, Kenneth L. Kehl
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100074-(2020)
JTO Clinical and Research Reports
JTO Clinical and Research Reports
Introduction: The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and NSCLC. Whether this association exists in patients wit
Autor:
Sweta Jonnalagadda, Alessio Cortellini, Nitika Sharma, Daria Gramenitskaya, Kevin O'Brien, Emma Mi, Mahvish Muzaffar, Shravanti Macherla, David J. Pinato, Shanker Polsani, Abdul Rafeh Naqash, Chipman Robert Geoffrey Stroud, Jussi Koivunen, James Clark, Rahim Jiwani, Paul R. Walker, Sanna Livanainen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background CRP is an acute-phase protein produced primarily in response to interleukin IL-6 via transcriptional activation of the STAT3. Recent data have provided mechanistic insights into the immune suppressive role of elevated CRP by elucidating it